Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Critical Limb Ischemia Overview | 10 | 1 |
| Therapeutics Development | 11 | 2 |
| Pipeline Products for Critical Limb Ischemia Overview | 11 | 1 |
| Pipeline Products for Critical Limb Ischemia Comparative Analysis | 12 | 1 |
| Critical Limb Ischemia Therapeutics under Development by Companies | 13 | 2 |
| Critical Limb Ischemia Therapeutics under Investigation by Universities/Institutes | 15 | 1 |
| Critical Limb Ischemia Pipeline Products Glance | 16 | 3 |
| Late Stage Products | 16 | 1 |
| Clinical Stage Products | 17 | 1 |
| Early Stage Products | 18 | 1 |
| Critical Limb Ischemia Products under Development by Companies | 19 | 2 |
| Critical Limb Ischemia Products under Investigation by Universities/Institutes | 21 | 1 |
| Critical Limb Ischemia Companies Involved in Therapeutics Development | 22 | 24 |
| AnGes MG, Inc. | 22 | 1 |
| Apceth GmbH &Co. KG | 23 | 1 |
| Athersys, Inc. | 24 | 1 |
| BiogenCell Ltd. | 25 | 1 |
| Caladrius Biosciences Inc | 26 | 1 |
| Cynata Therapeutics Limited | 27 | 1 |
| Hemostemix Ltd | 28 | 1 |
| Histocell S.L. | 29 | 1 |
| ID Pharma Co., Ltd. | 30 | 1 |
| Integene International Holdings LLC | 31 | 1 |
| Juventas Therapeutics, Inc. | 32 | 1 |
| Kasiak Research Private Limited | 33 | 1 |
| Kowa Company, Ltd. | 34 | 1 |
| Neurofx, Inc. | 35 | 1 |
| Pharmicell Co., Ltd. | 36 | 1 |
| Pluristem Therapeutics Inc. | 37 | 1 |
| ReNeuron Group Plc | 38 | 1 |
| Symic Biomedical, Inc. | 39 | 1 |
| Targazyme, Inc. | 40 | 1 |
| TikoMed AB | 41 | 1 |
| U.S. Stem Cell, Inc. | 42 | 1 |
| Vericel Corporation | 43 | 1 |
| VESSL Therapeutics Ltd | 44 | 1 |
| ViroMed Co Ltd | 45 | 1 |
| Critical Limb Ischemia Therapeutics Assessment | 46 | 9 |
| Assessment by Monotherapy Products | 46 | 1 |
| Assessment by Target | 47 | 2 |
| Assessment by Mechanism of Action | 49 | 2 |
| Assessment by Route of Administration | 51 | 2 |
| Assessment by Molecule Type | 53 | 2 |
| Drug Profiles | 55 | 77 |
| ACP-01 Drug Profile | 55 | 3 |
| AdipoCell Drug Profile | 58 | 3 |
| Alecmestencel-T Drug Profile | 61 | 1 |
| ASCT-01 Drug Profile | 62 | 1 |
| BC-1 Drug Profile | 63 | 1 |
| beperminogene perplasmid Drug Profile | 64 | 6 |
| Biologic to Activate FGF2 for Critical Limb Ischemia Drug Profile | 70 | 1 |
| Cellgram-CLI Drug Profile | 71 | 1 |
| CLBS-12 Drug Profile | 72 | 1 |
| DVC-10101 Drug Profile | 73 | 1 |
| FAB-117HC Drug Profile | 74 | 1 |
| Gene Therapy for Critical Limb Ischemia Drug Profile | 75 | 1 |
| ixmyelocel-T Drug Profile | 76 | 7 |
| JVS-100 Drug Profile | 83 | 5 |
| MultiGeneAngio Drug Profile | 88 | 1 |
| NFx-101 Drug Profile | 89 | 1 |
| NK-104 NP Drug Profile | 90 | 1 |
| PF-05285401 Drug Profile | 91 | 11 |
| PLX-PAD Drug Profile | 102 | 10 |
| Protein to Agonize LRP5 and LRP6 for Critical Limb Ischemia and Myocardial Infarction Drug Profile | 112 | 1 |
| Refacell-CLI Drug Profile | 113 | 1 |
| Rejuveinix Drug Profile | 114 | 1 |
| ReN-009 Drug Profile | 115 | 2 |
| SB-030 Drug Profile | 117 | 2 |
| Stem Cell Therapy for Cardiovacular Diseases and Asthma Drug Profile | 119 | 2 |
| Stem Cell Therapy for Critical Limb Ischemia Drug Profile | 121 | 1 |
| Stem Cell Therapy for Critical Limb Ischemia Drug Profile | 122 | 1 |
| TM-700 Drug Profile | 123 | 1 |
| TXA-302 Drug Profile | 124 | 1 |
| TZ-101 Drug Profile | 125 | 3 |
| VM-202 Drug Profile | 128 | 4 |
| Critical Limb Ischemia Dormant Projects | 132 | 2 |
| Critical Limb Ischemia Discontinued Products | 134 | 1 |
| Critical Limb Ischemia Product Development Milestones | 135 | 9 |
| Featured News &Press Releases | 135 | 1 |
| Oct 03, 2016: Hemostemix Announces it has been Granted two Additional Patents in the US and in Canada | 135 | 1 |
| Jun 20, 2016: AnGes Announces Amendment to the Global Development of HGF Plasmid for Critical Limb Ischemia | 135 | 1 |
| Apr 18, 2016: Hemostemix Receives IRB Approval from the Houston Methodist Hospital Research Institute and the University of California Los Angeles | 136 | 1 |
| Apr 18, 2016: Caladrius Reaches Agreement with Japanese Regulators on Development Plan for CD34 Cell Therapy for Critical Limb Ischemia | 137 | 1 |
| Jan 22, 2016: ViroMed Publishes Results from Critical Limb Ischemia Phase II Clinical Study | 137 | 1 |
| Dec 22, 2015: Hemostemix Poised to Expand Phase-2 Clinical Trial of Lead Product ACP-01 to the United States | 138 | 1 |
| Oct 05, 2015: Hemostemix to Present at 2015 Stem Cell Meeting on the Mesa | 139 | 1 |
| Sep 14, 2015: Hemostemix Executes Strategic Alliance with Hemostemix Asia for Expansion of Phase-2 Clinical Trial to Taiwan | 140 | 1 |
| Aug 12, 2015: Patient Enrollment Begins in Europe in the Global Phase III Clinical Trial of HGF Gene Therapy for Critical Limb Ischemia | 140 | 1 |
| Aug 10, 2015: Hemostemix Receives FDA Clearance for Phase-2 Clinical Trial of Lead Product ACP-01 in the United States | 140 | 1 |
| Jul 27, 2015: Hemostemix Enrolls 20th Participant and Treats 15th in International Clinical Trial for Critical Limb Ischemia | 141 | 1 |
| Jun 25, 2015: Hemostemix Enrolls Fifth Participant at Vancouver General Hospital in International Phase-2 Clinical Trial for Critical Limb Ischemia | 141 | 1 |
| Jun 18, 2015: Hemostemix Prepares Investigational New Drug Application for Review by U.S. Food and Drug Administration for Company s ACP-01 Formulation to Treat Critical Limb Ischemia | 142 | 1 |
| May 19, 2015: Hemostemix Receives Notice of Allowance for Additional U.S. Patent on ACP-01 Covering Autologous Cell Therapy for Critical Limb Ischemia | 142 | 1 |
| Apr 20, 2015: Hemostemix to Present at the 2015 Annual Meeting of the Clinical Trials Association in Israel | 143 | 1 |
| Appendix | 144 | 2 |
| Methodology | 144 | 1 |
| Coverage | 144 | 1 |
| Secondary Research | 144 | 1 |
| Primary Research | 144 | 1 |
| Expert Panel Validation | 144 | 1 |
| Contact Us | 144 | 1 |
| Disclaimer | 145 | 1 |